Presentation is loading. Please wait.

Presentation is loading. Please wait.

Correlation Between Polymorphisms of the Reduced Folate Carrier Gene (SLC19A1) and Survival After Pemetrexed-Based Therapy in Non-small Cell Lung Cancer:

Published byYenny Tedja Modified over 5 years ago

Similar presentations

Presentation on theme: "Correlation Between Polymorphisms of the Reduced Folate Carrier Gene (SLC19A1) and Survival After Pemetrexed-Based Therapy in Non-small Cell Lung Cancer:"— Presentation transcript:

1 Correlation Between Polymorphisms of the Reduced Folate Carrier Gene (SLC19A1) and Survival After Pemetrexed-Based Therapy in Non-small Cell Lung Cancer: A North Central Cancer Treatment Group-Based Exploratory Study  Araba A. Adjei, PhD, Oreste E. Salavaggione, MD, Sumithra J. Mandrekar, PhD, Grace K. Dy, MD, Katie L. Allen Ziegler, BS, Chiaki Endo, MD, Julian R. Molina, MD, PhD, Steven E. Schild, MD, Alex A. Adjei, MD, PhD  Journal of Thoracic Oncology  Volume 5, Issue 9, Pages (September 2010) DOI: /JTO.0b013e3181ec18c4 Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Kaplan-Meier estimates for patients with non-small cell lung cancer (NSCLC) undergoing pemetrexed and gemcitabine combination therapy. Median overall survival (OS) was plotted by SLC19A1 IVS4(2117)C>T polymorphism (rs ): CC versus CT versus TT genotypes; CC: N = 12, number of events = 12; CT: N = 26, number of events = 21; and TT: N = 16, number of events = 12. Journal of Thoracic Oncology 2010 5, DOI: ( /JTO.0b013e3181ec18c4) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 Kaplan-Meier estimates for patients with non-small cell lung cancer (NSCLC) undergoing pemetrexed and gemcitabine combination therapy. A, Median overall survival (OS) was plotted by SLC19A1 IVS5(9148)C>A polymorphism (rs ): CC versus CA versus AA genotypes; CC: N = 12, number of events = 12; CA: N = 24, number of events = 19; and AA: N = 18, number of events = 14. B, Median OS was plotted by SLC19A1 exon6(2522)C>T polymorphism (rs ): CC versus CT versus TT genotypes; CC: N = 18, number of events = 14; CT: N = 24, number of events = 19; and TT: N = 12, number of events = 12. Frequency distributions of genotypes at loci were equal. Journal of Thoracic Oncology 2010 5, DOI: ( /JTO.0b013e3181ec18c4) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3 Kaplan-Meier estimates for patients with non-small cell lung cancer (NSCLC) undergoing pemetrexed and gemcitabine combination therapy. Median overall survival (OS) was plotted by SLC19A1 IVS2(4935)G>A polymorphism (rs914232): GG versus GA versus AA genotypes: GG: N = 20, number of events = 16; GA: N = 23, number of events = 18; and AA: N = 11, number of events = 11. Journal of Thoracic Oncology 2010 5, DOI: ( /JTO.0b013e3181ec18c4) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Correlation Between Polymorphisms of the Reduced Folate Carrier Gene (SLC19A1) and Survival After Pemetrexed-Based Therapy in Non-small Cell Lung Cancer:"

Similar presentations

Su K. Metcalfe, MD, MPH, Michael T

Su K. Metcalfe, MD, MPH, Michael T
Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis  Ian Cromwell, MSc, Kimberly.

Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis  Ian Cromwell, MSc, Kimberly.
Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,

Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,
Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.
Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.
Phase II Trial with Carboplatin and Bendamustine in Patients with Extensive Stage Small-Cell Lung Cancer  Wolf Köster, MD, Andrea Heider, MD, Norbert.

Phase II Trial with Carboplatin and Bendamustine in Patients with Extensive Stage Small-Cell Lung Cancer  Wolf Köster, MD, Andrea Heider, MD, Norbert.
Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 
The Role of Radiation Therapy in Malignant Thymoma: A Surveillance, Epidemiology, and End Results Database Analysis  Annemarie T. Fernandes, BA, Eric.

The Role of Radiation Therapy in Malignant Thymoma: A Surveillance, Epidemiology, and End Results Database Analysis  Annemarie T. Fernandes, BA, Eric.
Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.
Incidence and Survival of Malignant Pleural Mesothelioma in Norway: A Population- Based Study of 1686 Cases  Åslaug Helland, MD, PhD, Steinar Solberg,

Incidence and Survival of Malignant Pleural Mesothelioma in Norway: A Population- Based Study of 1686 Cases  Åslaug Helland, MD, PhD, Steinar Solberg,
ERCC2/XPD Lys751Gln and Asp312Asn Gene Polymorphism and Lung Cancer Risk: A Meta-Analysis Involving 22 Case–Control Studies  Ping Zhan, MD, Qin Wang,

ERCC2/XPD Lys751Gln and Asp312Asn Gene Polymorphism and Lung Cancer Risk: A Meta-Analysis Involving 22 Case–Control Studies  Ping Zhan, MD, Qin Wang,
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
Patterns of Care and Treatment Outcomes of Elderly Patients with Stage I Esophageal Cancer: Analysis of the National Cancer Data Base  Amy C. Moreno,

Patterns of Care and Treatment Outcomes of Elderly Patients with Stage I Esophageal Cancer: Analysis of the National Cancer Data Base  Amy C. Moreno,
Association of the CHRNA3 Locus with Lung Cancer Risk and Prognosis in Chinese Han Population  Xiaomin Niu, MD, Zhiwei Chen, MD, PhD, Shengping Shen,

Association of the CHRNA3 Locus with Lung Cancer Risk and Prognosis in Chinese Han Population  Xiaomin Niu, MD, Zhiwei Chen, MD, PhD, Shengping Shen,
Endpoints in Phase II Trials for Advanced Non-small Cell Lung Cancer

Endpoints in Phase II Trials for Advanced Non-small Cell Lung Cancer
DNA Repair Polymorphisms and Treatment Outcomes of Patients with Malignant Mesothelioma Treated with Gemcitabine-Platinum Combination Chemotherapy  Nina.

DNA Repair Polymorphisms and Treatment Outcomes of Patients with Malignant Mesothelioma Treated with Gemcitabine-Platinum Combination Chemotherapy  Nina.
Treatment and Prognosis of Isolated Local Relapse after Stereotactic Body Radiotherapy for Clinical Stage I Non-Small-Cell Lung Cancer  Masatsugu Hamaji,

Treatment and Prognosis of Isolated Local Relapse after Stereotactic Body Radiotherapy for Clinical Stage I Non-Small-Cell Lung Cancer  Masatsugu Hamaji,
The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer  Peter Goldstraw, MB, FRCS, John J. Crowley, PhD 

The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer  Peter Goldstraw, MB, FRCS, John J. Crowley, PhD 
Jann N. Sarkaria, MD, Paul Schwingler, Steven E. Schild, MD, Patrick T

Jann N. Sarkaria, MD, Paul Schwingler, Steven E. Schild, MD, Patrick T
Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

Similar presentations

Ads by Google